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BACKGROUND
Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthma-
related death among adults and the risk of asthma-related hospitalization among 
children. It is unknown whether the concomitant use of inhaled glucocorticoids 
with LABAs mitigates those risks. This trial prospectively evaluated the safety of 
the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination 
in children.
METHODS
We randomly assigned, in a 1:1 ratio, children 4 to 11 years of age who required 
daily asthma medications and had a history of asthma exacerbations in the previ-
ous year to receive fluticasone propionate plus salmeterol or fluticasone alone for 
26 weeks. The primary safety end point was the first serious asthma-related event 
(death, endotracheal intubation, or hospitalization), as assessed in a time-to-event 
analysis. The statistical design specified that noninferiority would be shown if the 
upper boundary of the 95% confidence interval of the hazard ratio for the primary 
safety end point was less than 2.675. The main efficacy end point was the first 
severe asthma exacerbation that led to treatment with systemic glucocorticoids, as 
assessed in a time-to-event analysis.
RESULTS
Among the 6208 patients, 27 patients in the fluticasone–salmeterol group and 21 in 
the fluticasone-alone group had a serious asthma-related event (all were hospital-
izations); the hazard ratio with fluticasone–salmeterol versus fluticasone alone was 
1.28 (95% confidence interval [CI], 0.73 to 2.27), which showed the noninferiority 
of fluticasone–salmeterol (P = 0.006). A total of 265 patients (8.5%) in the fluticasone–
salmeterol group and 309 (10.0%) in the fluticasone-alone group had a severe 
asthma exacerbation (hazard ratio, 0.86; 95% CI, 0.73 to 1.01).
CONCLUSIONS
In this trial involving children with asthma, salmeterol in a fixed-dose combina-
tion with fluticasone was associated with the risk of a serious asthma-related event 
that was similar to the risk with fluticasone alone. (Funded by GlaxoSmithKline; 
VESTRI ClinicalTrials.gov number, NCT01462344.)
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The safety of inhaled beta-agonists in patients with asthma has been debated since the 1960s.1-5 After the introduction 
of long-acting beta-agonists (LABAs) in the 1990s 
and the findings of two studies involving adults, 
attention focused on a potential association of 
LABAs with an increased risk of asthma-related 
death.6,7 A 2008 meta-analysis conducted by the 
Food and Drug Administration (FDA) showed a 
higher risk of asthma-related events (death, intu-
bation, or hospitalization) among patients receiv-
ing LABAs than among patients not receiving 
these medications.8 In a subsequent meta-analysis, 
a higher risk of serious asthma-related events 
was observed with salmeterol than with non-
LABA agents among patients who received no 
inhaled glucocorticoids and among those who 
received inhaled glucocorticoids as background 
maintenance medication or in an inhaler that 
was separate from the one with salmeterol.9 In 
contrast, there were no asthma-related deaths 
and the risk of asthma-related hospitalization or 
intubation was not higher when salmeterol was 
delivered in a fixed-dose combination with in-
haled glucocorticoids than when inhaled glucocor-
ticoids were received alone.9 The recent AUSTRI 
trial involving adolescents and adults showed that 
the risk of serious asthma-related events was not 
higher among patients receiving a LABA in a 
fixed-dose combination with an inhaled gluco-
corticoid than among those receiving inhaled 
glucocorticoid monotherapy.10
Clinical-trial experience regarding the safety of 
LABAs in children 4 to 11 years of age is limited.11 
A review of the 2008 FDA meta-analysis high-
lights that this age group has the highest risk of 
serious asthma-related events, primarily hospital-
ization.8,12 This analysis identified that the risk 
of hospitalization among children was mitigated 
when LABAs were used concomitantly with in-
haled glucocorticoids,9 a finding that was simi-
lar to the results in studies involving adults. To 
address the questions raised by the FDA meta-
analysis and the limited clinical-trial experience 
in children, the FDA requested that GlaxoSmith-
Kline, the only U.S. manufacturer of a LABA with 
a pediatric asthma indication, perform a large 
safety trial with the primary objective of deter-
mining whether fluticasone propionate–salmet-
erol was noninferior to fluticasone alone with 
respect to the risk of a serious asthma-related 
event among children with persistent asthma 
and a history of a severe exacerbation. The sec-
ondary objective was to assess whether the com-
bination was superior to f luticasone alone in 
terms of the risk of severe asthma exacerbations.
Me thods
Trial Design and Oversight
We conducted this international, randomized, 
double-blind, active-comparator, 26-week trial 
from November 2011 through November 2015 at 
567 trial centers in 32 countries (Fig. S1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org). The trial proto-
col, including the statistical analysis plan, is avail-
able at NEJM.org.
A pediatric steering committee reviewed per-
formance standards, a pediatric adjudication com-
mittee, whose members were unaware of the 
treatment assignments, determined the related-
ness of end points to asthma, and an indepen-
dent data and safety monitoring committee re-
viewed safety data every 6 months, with one 
planned interim statistical analysis after approxi-
mately half the expected 43 events occurred (see 
the Supplementary Appendix). Scientific over-
sight was provided by employees of the sponsor 
(GlaxoSmithKline) who were collectively respon-
sible for the trial design and conduct. The pedi-
atric steering committee and the FDA advised 
GlaxoSmithKline on the trial design, which was 
harmonized with that of the AUSTRI trial, the 
GlaxoSmithKline-sponsored trial that involved 
adolescents and adults.10
The initial draft of the manuscript was writ-
ten by the first and second authors, and all the 
authors collaborated to prepare the final content 
for submission. Editorial support was provided 
by two professional writers, paid by the sponsor. 
Statistical analyses were performed by employees 
of GlaxoSmithKline and Parexel International. 
All the authors had full access to the data and 
vouch for the accuracy and completeness of all 
data and analyses and for the fidelity of this 
report to the protocol. All the authors made the 
decision to submit the manuscript for publi-
cation.
Ethical approval was obtained from the rele-
vant ethics committees and institutional review 
boards. The trial was conducted in accordance 
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with Good Clinical Practice guidelines and the 
provisions of the Declaration of Helsinki.
Trial Population
Key inclusion criteria were an age of 4 to 11 years, 
consistent use of asthma medication during the 
4 weeks before enrollment, the Childhood Asthma 
Control Test (C-ACT)13 score (on a scale from 0 to 
27, with higher scores indicating better control 
of asthma13; minimally important difference, 
1.6 points14), and a history of asthma exacerba-
tion in the previous 12 months, with no exacer-
bation occurring during the 30 days before ran-
domization (Table S1 in the Supplementary 
Appendix). Patients were excluded if they had a 
history of life-threatening asthma or unstable 
asthma (see the Supplementary Appendix). Chil-
dren whose asthma was controlled by inhaled 
glucocorticoids and a LABA were enrolled on the 
basis of the U.S. label for fluticasone–salmeterol, 
which states, “once asthma control is achieved 
and maintained, assess the patient at regular 
intervals and step down therapy.”15 Investigators 
were instructed to enroll patients only if either 
treatment option (f luticasone–salmeterol or 
f luticasone alone) would be appropriate. The 
parent or legal guardian provided written in-
formed consent. Assent by patients was given 
as appropriate.
Randomization, Treatments, and Blinding
Patients were randomly assigned, in a 1:1 ratio, 
to receive fluticasone–salmeterol or fluticasone 
alone, on the basis of pretrial medication, C-ACT 
score, and exacerbation history, to receive one 
of four treatments: a fixed-dose combination of 
fluticasone propionate at a dose of 100 μg plus 
salmeterol at a dose of 50 μg, a fixed-dose com-
bination of fluticasone at a dose of 250 μg plus 
salmeterol at a dose of 50 μg, fluticasone alone 
at a dose of 100 μg, or fluticasone alone at a 
dose of 250 μg (Table S1 in the Supplementary 
Appendix). Treatment was administered twice 
daily with the use of Diskus devices (GlaxoSmith-
Kline) that were identical for all regimens to 
maintain blinding. Treatment was administered 
in a double-blind manner with respect to the use 
of salmeterol but not with respect to the dose 
of f luticasone propionate. Rescue therapy with 
albuterol (also known as salbutamol) was sup-
plied to all patients by means of a metered-dose 
inhaler.
Trial End Points
Safety End Points and Assessments
The primary end point was the first serious 
asthma-related event (a composite end point that 
included death, endotracheal intubation, and hos-
pitalization), as assessed in a time-to-event analy-
sis. All intubations and deaths were fully adjudi-
cated. All hospitalizations were screened by one 
committee member, and those that were deemed 
to be potentially related to asthma were fully ad-
judicated. All nonserious adverse events that led 
to the discontinuation of treatment and all seri-
ous adverse events were documented. The vital 
status of all the patients who received at least one 
dose of treatment was assessed at the end of the 
6-month trial period. Height was measured with 
the use of standard clinical-office procedures.
Efficacy End Points
The primary efficacy end point was the first 
severe asthma exacerbation, as assessed in a 
time-to-event analysis; a severe asthma exacer-
bation was defined as asthma deterioration lead-
ing to the use of systemic glucocorticoids for at 
least 3 days or a depot injection of glucocorti-
coids, according to the physician’s clinical judg-
ment (see the Supplementary Appendix). The 
main objective with respect to efficacy was to 
determine whether fluticasone–salmeterol was 
superior to fluticasone alone in terms of the first 
severe asthma exacerbation. Asthma exacerba-
tions were recorded independently of adverse 
events, and withdrawal from the trial was at the 
discretion of the investigator. Secondary efficacy 
end points included the number of rescue therapy–
free days and the number of asthma-control days.
Statistical Analysis
The primary safety end point was assessed by a 
stratified Cox proportional-hazards regression 
model, with terms for randomized treatment 
(fluticasone–salmeterol or fluticasone alone) and 
randomization stratum. If the resulting estimate 
of the upper boundary of the 95% confidence 
interval for the hazard ratio for the first serious 
asthma-related event in the time-to-event analy-
sis (f luticasone–salmeterol as compared with 
fluticasone alone) was less than 2.675, noninfe-
riority was concluded. The noninferiority margin 
was based on the event rate observed in the 
meta-analysis of LABA-containing products con-
ducted in 20088 and also factored in the sample 
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size and time period that were required to com-
plete the trial. The main efficacy objective — to 
determine whether f luticasone–salmeterol was 
superior to fluticasone alone in terms of the first 
severe asthma exacerbation — was tested with 
the use of a Cox proportional-hazards regression 
model.
Within each treatment group, data from the 
two dose subgroups were combined (fluticasone–
salmeterol 100/50 μg and 250/50 μg; fluticasone 
alone 100 μg and 250 μg). The trial was not 
powered to allow the formal statistical compari-
son or evaluation of fluticasone–salmeterol ver-
sus f luticasone alone in subgroups. Descriptive 
analyses were performed for the subgroups of 
age and race, with results expressed as hazard 
ratios and 95% confidence intervals.
In calculating the sample size for the primary 
safety end point, we assumed a rate of 0.007 
patients with an event in the fluticasone-alone 
group over the 26-week trial period. The sample 
size was adjusted to accommodate one interim 
statistical analysis, which was to be conducted 
when approximately half the expected number of 
composite end points had occurred. The Haybittle–
Peto method was used for managing the alpha-
spending function over the interim analysis and 
the final analysis.16,17 We calculated that a sam-
ple of 6202 patients would allow the observation 
of 43 patients having a composite end-point event, 
which would provide the trial with 90% power 
to show the noninferiority of fluticasone–salmet-
erol to fluticasone alone with the use of a log-
rank test, at a one-sided alpha level of 0.025, and 
to reject the null hypothesis that the risk associ-
ated with fluticasone–salmeterol versus flutica-
sone alone was greater than the noninferiority 
margin.
The intention-to-treat population, which in-
cluded all the patients who underwent random-
ization and received at least one dose of trial 
medication, was used for the analysis of the 
primary end point. Events were included in the 
analysis during the entire 6-month trial period 
even if the treatment was discontinued early or 
until 7 days after the last dose of treatment, 
whichever was the longer interval from random-
ization. A modified intention-to-treat population 
was used for efficacy analyses, which included 
only data collected up to 7 days after each pa-
tient stopped the trial medication. Four effi-
cacy subgroups were determined on the basis 
of asthma control at baseline, exacerbation his-
tory, and previous asthma therapy (Table S2 in 
the Supplementary Appendix).
R esult s
Trial Population
The intention-to-treat population included 3107 
patients in the fluticasone–salmeterol group and 
3101 in the fluticasone-alone group (Fig. 1). The 
characteristics of age, sex, race, baseline C-ACT 
score, and season of enrollment (season of en-
rollment was analyzed post hoc) were similar in 
the two overall treatment groups (Table 1, and 
Table S3 in the Supplementary Appendix). The 
median rate of adherence to the trial regimen, as 
determined by the dose counter in the Diskus 
device, was 94% in each treatment group (Table 
S4 in the Supplementary Appendix).
Safety
Prespecified Primary Safety End Point
Of the 6208 patients in the intention-to-treat 
population, 48 had a serious asthma-related 
event (27 patients in the f luticasone–salmeterol 
group and 21 in the f luticasone-alone group) 
(Table 2). Only asthma-related hospitalizations 
were reported; there were no deaths or asthma-
related endotracheal intubations in either treat-
ment group (Table 2). The hazard ratio for a 
serious asthma-related event (fluticasone–salmet-
erol vs. fluticasone alone) was 1.28 (95% confi-
dence interval [CI], 0.73 to 2.27). The upper 
boundary of the 95% confidence interval was 
less than 2.675, which showed the noninferior-
ity of fluticasone–salmeterol to fluticasone alone 
(P = 0.006). The Kaplan–Meier curves for the first 
event of the composite end point in the time-
to-event analysis are shown in Figure 2. The 
event rates in subgroups defined according to 
age, race, and sex were all less than 2% of the 
defined populations for each treatment group 
(Table 2).
Other Safety End Points
A total of 34 children (1.1%) in the fluticasone–
salmeterol group and 35 (1.1%) in the f lutica-
sone-alone group withdrew owing to an asthma 
exacerbation. A total of 56 patients (1.8%) in the 
fluticasone–salmeterol group and 54 (1.7%) in 
the fluticasone-alone group had a serious adverse 
event (Table S5 in the Supplementary Appendix). 
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The growth velocity was 2.712 cm per 6 months 
in the subgroup that received 100 μg of flutica-
sone and 2.657 cm per 6 months in the sub-
group that received 250 μg of fluticasone (differ-
ence, −0.055 cm per 6 months; 95% CI, −0.190 
to 0.079).
Prespecified Efficacy End Points
Primary End Point
A total of 265 patients (8.5%) in the fluticasone–
salmeterol group and 309 (10.0%) in the flutica-
sone-alone group had one or more severe asth-
ma exacerbations (Table 3). The hazard ratio in 
Figure 1. Randomization and Treatment of the Patients.
Patients may have met more than one criterion for exclusion.
6250 Underwent randomization
42 Never received trial drug
6208 Were included in the intention-
to-treat population
6759 Patients were screened, including
126 who were rescreened and
underwent randomization
635 Were excluded 
1 Had an adverse event
21 Were lost to follow-up
73 Were withdrawn by investigator
463 Did not meet entry criteria
76 Withdrew
1 Was missing
3107 Were assigned to receive fluticasone–
salmeterol
1269 Were assigned to receive 100 µg
of fluticasone and 50 µg of
salmeterol
1838 Were assigned to receive 250 µg
of fluticasone and 50 µg of
salmeterol
3101 Were assigned to receive fluticasone
alone
1267 Were assigned to receive 100 µg
1834 Were assigned to receive 250 µg
2 Were withdrawn from trial
1 Was enrolled in error
because trial had ended
1 Withdrew
2 Withdrew from trial
383 Discontinued treatment
24 Had adverse event
34 Had asthma exacerbation
5 Had lack of efficacy
7 Were lost to follow-up
68 Had protocol deviation
245 Withdrew
350 Discontinued treatment
23 Had adverse event
35 Had asthma exacerbation
6 Had lack of efficacy
7 Were lost to follow-up
53 Had protocol deviation
226 Withdrew
3099 Completed the trial
2751 Completed treatment
3105 Completed the trial
2724 Completed treatment
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the time-to-event analysis of the first severe 
asthma exacerbation with fluticasone–salmeter-
ol versus fluticasone alone was 0.86 (95% CI, 
0.73 to 1.01) when age was included as a covari-
ate. Among black patients, 6.7% of the patients 
in the fluticasone–salmeterol group and 8.4% of 
those in the fluticasone-alone group had a severe 
exacerbation (hazard ratio, 0.80; 95% CI, 0.51 to 
1.24). There was no apparent between-group dif-
ference in the number of patients who had a se-
vere exacerbation in each of the age groups (4 to 
6 years and 7 to 11 years) (Table 3).
Prespecified Secondary Efficacy End Points
For further insight into the efficacy of the LABA, 
we compared four prespecified subgroups that 
included 86.3% of the trial population to reflect 
changes from baseline therapy (addition, main-
tenance, or withdrawal of the LABA) (Table 3); 
13.7% of the patients did not meet the criteria 
for the prespecified subgroups. Among patients 
in subgroup 1, who entered the trial with asthma 
controlled by combined inhaled glucocorticoid 
and LABA therapy, fewer patients who continued 
to take combination therapy had a severe exac-
erbation than those who had LABA withdrawn 
(i.e., who were treated with fluticasone alone) 
(7.5% vs. 9.9%; hazard ratio, 0.75; 95% CI, 0.57 
to 0.98). In subgroup 2, patients entered the trial 
with asthma that was uncontrolled by low-dose 
glucocorticoid and LABA therapy and had their 
dose of inhaled glucocorticoid increased. Fewer 
patients in this group who were treated with 
fluticasone–salmeterol had a severe exacerbation 
than those who had the LABA withdrawn and 
were treated with fluticasone alone at a dose of 
250 μg (11.3% vs. 15.2%; hazard ratio, 0.73; 
95% CI, 0.52 to 1.03). Among patients in sub-
group 3, who had uncontrolled asthma and en-
tered the trial while taking an inhaled gluco-
corticoid only, the addition of the LABA to 
fluticasone at a dose of 250 μg resulted in 7.2% 
having a severe exacerbation, as compared with 
8.0% with a severe exacerbation among those 
who were treated with fluticasone alone at a 
dose of 250 μg (hazard ratio, 0.91; 95% CI, 0.62 
to 1.33). Among patients in subgroup 4, who 
entered the trial with asthma that was controlled 
by inhaled glucocorticoid treatment only and who 
had had two or more exacerbations in the previ-
ous year, 12.5% of those who had the LABA 
added had a severe exacerbation, as compared 
with 9.7% who continued taking fluticasone 
alone (hazard ratio, 1.35; 95% CI, 0.81 to 2.25) 
(Table 3).
Rescue Therapy–free Days and Asthma Control
The mean percentage of rescue therapy–free days 
was similar in the fluticasone–salmeterol group 
and the fluticasone-alone group (83.0% and 
81.9%, respectively), as was the mean percentage 
of days with asthma controlled (74.8% and 
73.4%, respectively) (Table S6 in the Supplemen-
tary Appendix). The C-ACT score showed that 
53.1% of all patients had asthma controlled at 
baseline and that 88.1% of the patients in the 
fluticasone–salmeterol group and 88.5% of those 
in the fluticasone-alone group had asthma con-
trolled at the end of the trial.
Characteristic
Fluticasone–Salmeterol 
(N = 3107)
Fluticasone Alone 
(N = 3101)
Male sex — no. (%) 1920 (61.8) 1874 (60.4)
Age
Mean — yr 7.6±2.2 7.6±2.2
Distribution — no. (%)
4–6 yr 1096 (35.3) 1114 (35.9)
7–11 yr 2011 (64.7) 1987 (64.1)
Race — no. (%)†
White 1998 (64.3) 2032 (65.5)
Black 539 (17.3) 511 (16.5)
Other 570 (18.3) 558 (18.0)
Geographic region — no. (%)
North America 1439 (46.3) 1433 (46.2)
Latin America 335 (10.8) 322 (10.4)
Europe 774 (24.9) 789 (25.4)
Africa 350 (11.3) 349 (11.3)
Asia–Pacific 209 (6.7) 208 (6.7)
Asthma duration — yr 4±2.8 4±2.7
*  Plus–minus values are means ±SD. The analysis was performed in the intention-
to-treat population, which included all the patients who had undergone random-
ization and received at least one dose of fluticasone–salmeterol or fluticasone 
alone. There were no imbalances in the characteristics at baseline between the 
treatment groups.
†  Race was self-reported.
Table 1. Characteristics of the Patients at Baseline.*
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Discussion
The VESTRI trial was conducted to detect whether 
there is excess risk associated with the addition 
of a LABA to maintenance inhaled glucocorti-
coids among children with asthma. The observed 
end points fell within the prespecified noninfe-
riority margin with respect to the risk of serious 
asthma-related events associated with salmeterol 
delivered in a fixed-dose combination with fluti-
casone propionate, as compared with equipotent 
doses of fluticasone alone. The safety findings 
in this trial concur with those of previous meta-
analyses that compared a fixed-dose combina-
tion of a LABA with inhaled glucocorticoids and 
with the results of the AUSTRI trial, which in-
volved 11,751 adolescents and adults and which 
was similar in design to the current trial.8,9,10
Asthma-related deaths are uncommon in chil-
dren, and no association with LABAs has been 
reported previously.8,12 No deaths or asthma-
related intubations occurred in our trial. The hos-
pitalization rate in our trial was approximately 
1.5 hospitalizations per 100 patient-years with 
each treatment, which is consistent with the in-
cidence observed by the U.S. National Surveil-
lance of Asthma among children 5 to 14 years of 
age.18 The low event rate precluded meaningful 
interpretation of differences in numbers of events 
in subgroups according to age, race, or sex. 
These safety comparisons were not powered to 
detect noninferiority and the event rates were 
numerically consistent with data in the AUSTRI 
trial, including data from adolescents.10
The entry criteria in our trial were selected 
primarily for the safety analysis. More than half 
the patients entered the study with a C-ACT 
score that showed asthma control, and there was 
no pretreatment run-in phase to establish base-
line medication requirements. Given the vari-
ability in the baseline characteristics, efficacy 
subgroups were prespecified to address differ-
ences in asthma control and previous medication 
use. We found that the number of patients who 
had a severe asthma exacerbation was 14% lower 
among children receiving fluticasone–salmeterol 
than among those receiving fluticasone alone — 
a nonsignificant difference.
Of the overall trial population, 54.9% of the 
patients were in efficacy subgroups 1 and 2 
Safety End Point
Fluticasone–Salmeterol 
(N = 3107)
Fluticasone Alone 
(N = 3101)
Composite safety end point — no. (%) 27 (0.9) 21 (0.7)
Asthma-related death 0 0
Asthma-related intubation 0 0
Asthma-related hospitalization 27 (0.9) 21 (0.7)
Total no. of asthma-related hospitalizations* 28 22
Patients hospitalized — no./total no. (%)
According to age
4–6 yr 11/1096 (1.0) 10/1114 (0.9)
7–11 yr 16/2011 (0.8) 11/1987 (0.6)
According to race
White 11/1998 (0.6) 13/2032 (0.6)
Black 6/539 (1.1) 3/511 (0.6)
Other 10/570 (1.8) 5/558 (0.9)
According to sex
Female 12/1187 (1.0) 4/1227 (0.3)
Male 15/1920 (0.8) 17/1874 (0.9)
*  One patient in each treatment group was not withdrawn from the trial after the first hospitalization and was hospital-
ized a second time.
Table 2. Composite Safety End Points and Hospitalizations, According to Age, Race, and Sex, in the Intention-to-Treat 
Population.
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(Table 3) and entered the trial while taking com-
bination treatment with an inhaled glucocorti-
coid and a LABA. The number of patients who 
had a severe asthma exacerbation was 25% lower 
among children who continued taking flutica-
sone–salmeterol than among those who switched 
to fluticasone alone. This finding suggests the 
need to understand better the appropriate clini-
cal variables that need to be assessed before 
patients step down from combination therapy. 
Patients in subgroup 3 had uncontrolled asthma 
at baseline and had differing baseline medica-
tions, and the addition of a LABA had no signifi-
cant effect. In subgroup 4, the number of chil-
dren who had a severe exacerbation was not 
significantly lower among children whose asthma 
was controlled with the use of low- or medium-
dose inhaled glucocorticoid monotherapy and 
who had salmeterol added than among those 
who continued glucocorticoid monotherapy; this 
finding supports present asthma guidelines that 
do not recommend adjunctive therapy for pa-
tients whose asthma is adequately controlled 
with the use of inhaled glucocorticoids.19,20
The evidence supporting the role of LABAs in 
children whose asthma is uncontrolled by low-
dose inhaled glucocorticoids is limited by the 
fact that few clinical trials involving children 
have had efficacy as a primary end point. Two 
studies that included children 4 to 11 years of 
age whose asthma was inadequately controlled by 
inhaled glucocorticoids showed an improvement in 
lung function and a resolution or abatement of 
symptoms with the addition of a LABA.21,22 An-
other study showed that the addition of salmet-
erol to fluticasone was equivalent to doubling the 
dose of fluticasone in children whose asthma was 
inadequately controlled by a moderate dose of 
inhaled glucocorticoids.23 The Best Add-on Ther-
apy Giving Effective Responses (BADGER) study, 
which compared three step-up treatment options 
in children whose asthma was poorly controlled 
by low-dose inhaled glucocorticoids, showed 
that the addition of a LABA to the inhaled glu-
cocorticoid was the best treatment option among 
the three options studied (the other options were 
increasing the dose of the inhaled glucocorticoid 
and adding a leukotriene antagonist).24
Figure 2. First Occurrence of Serious Asthma-Related Event in the Time-to-Event Analysis.
The end point was assessed in the intention-to-treat population, which included all the patients who had undergone 
randomization and received at least one dose of fluticasone–salmeterol or fluticasone alone. The inset shows the 
same data on an expanded y axis. I bars indicate standard errors.
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The limitations of this trial include the short 
(6-month) duration and the infrequent occur-
rence of serious asthma-related events. Other 
limitations include the following: first, the trial 
excluded patients with multiple previous asthma-
related hospitalizations and intubations, and its 
findings may not be applicable to children with 
very severe asthma. The trial was designed with 
FDA guidance to assess a composite end point of 
serious asthma-related events. However, only 
asthma-related hospitalizations were observed. 
Second, it is not known whether the results of 
this trial are applicable to other combinations of 
inhaled glucocorticoids and LABAs. Third, poten-
tial concomitant risk factors such as allergen 
sensitivity were not addressed in this analysis. 
Fourth, the adherence to the medication regimen 
was higher than that seen in clinical practice; 
however, adherence is important when testing 
the risk associated with a drug to ensure that 
patients have maximal exposure to the drug.25 
Fifth, because of the small number of patients 
(48) who were hospitalized, we were unable to 
test differences according to race, age, or sex. 
Finally, height data did not include growth ve-
locity at baseline, a stadiometer was not used, 
and the data were not limited to prepubescent 
children.
This trial extends the safety findings of the 
AUSTRI trial to the pediatric age group.10 In 
conclusion, the results of the VESTRI trial 
showed that salmeterol given in combination 
with fluticasone propionate did not result in a 
higher risk of severe asthma events among chil-
dren 4 to 11 years of age than fluticasone alone.
Supported by GlaxoSmithKline.
Dr. Stempel, Dr. Yeakey, Dr. Lee, Dr. Raphiou, Ms. Buaron, 
Dr. Yun Kirby, and Dr. Pascoe are employees of and hold stock in 
GlaxoSmithKline. Mr. Kral and Ms. Prillaman are former em-
ployees of and hold stock in GlaxoSmithKline; Mr. Kral now 
works at GlaxoSmithKline on contract, and Ms. Prillaman is a 
current employee of Parexel International working on behalf of 
GlaxoSmithKline. Dr. Szefler reports receiving consulting fees, 
paid to his institution, from Roche, AstraZeneca, Aerocrine, 
Daiichi-Sankyo, Boehringer Ingelheim, grant support from 
GlaxoSmithKline, serving on an advisory panel for Merck, par-
ticipating in manuscript preparation and advisory boards for a 
study funded by Genentech, and participating in the develop-
ment of a study funded by Novartis; Dr. Pedersen, receiving con-
Subgroup Fluticasone–Salmeterol Fluticasone Alone
Hazard Ratio 
(95% CI)
no. of patients with exacerbation/ 
no. of patients (%)
Overall population 265/3107 (8.5) 309/3101 (10.0) 0.86 (0.73–1.01)
Black race 36/539 (6.7) 43/511 (8.4) 0.80 (0.51–1.24)
Age
4–6 yr 100/1096 (9.1) 118/1114 (10.6) 0.84 (0.65–1.10)
7–11 yr 165/2011 (8.2) 191/1987 (9.6) 0.87 (0.71–1.07)
Efficacy subgroup†
Subgroup 1: Maintenance of combination LABA–glucocorticoid 
therapy vs. glucocorticoid monotherapy in patients with 
controlled asthma
90/1208 (7.5) 120/1208 (9.9) 0.75 (0.57–0.98)
Subgroup 2: Maintenance of LABA therapy and increased dose 
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56/497 (11.3) 75/494 (15.2) 0.73 (0.52–1.03)
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*  Severe exacerbations were recorded from the start of treatment until 7 days after the stopping of the treatment (modified intention-to-treat 
population). CI denotes confidence interval, and LABA long-acting beta-agonist.
†  The four efficacy subgroups, which included 86.3% of the trial population, were formed to reflect changes from baseline therapy (addition, 
maintenance, or withdrawal of LABA).
Table 3. First Severe Asthma Exacerbation in the Time-to-Event Analysis, According to Overall Population Subgroup, in the Modified 
Intention-to-Treat Population.*
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